The company shared interim results from an ongoing Phase II trial examining its recombinant antibody fusion protein.

Background: Heart failure is a complex and multifactorial disease that affects millions globally, posing significant challenges to healthcare systems.

In the first 22 months of a mavacamten REMS program, few patients needed a temporary interruption in treatment for LVEF below 50%.

"These findings reinforce the use of dapagliflozin, 10 mg, or other SGLT2 inhibitors when the therapeutic goal is to reduce ...

With the growing trend of heavier cattle and carcass weights, packers are seeing higher rates of bovine congestive heart ...

Alleviant Medical announced that it received FDA investigational device exemption and breakthrough device designation for its atrial shunt.

Alleviant Medical announced today that it brought in $90 million to fund the second pivotal trial of its atrial shunt ...

Cardiovascular management strategies are essential to individuals with chronic lymphocytic leukemia (CLL) or multiple myeloma (MM) undergoing active treatment, due to the high rate of atrial ...

Salubris Biotherapeutics, Inc. (SalubrisBio), a clinical-stage biotechnology company dedicated to discovering and developing ...

Benefiting from technological and conceptual groundwork and positive early data, gene therapies are advancing in the clinic ...

reduced ejection fraction. Women present differently with heart failure and respond differently to certain treatments. Women with heart failure with preserved ejection fraction have sex-specific ...

Mina Makar highlights AstraZeneca's commitment to advancing heart failure research and innovative therapies, addressing ...